Co-designing a Patient Support Program for a Multiple Myeloma therapy
Sunday, November 12, 2023
Atlantis Health co-authored a poster presented at the International Myeloma Society Annual Meeting in Athens and at Blood 2023, the Annual Scientific Meeting of the Haematology Society of Australia and New Zealand. We described a co-designed patient support program delivered by Atlantis Health that offered personalized, multichannel support to patients at key time points aligned with their XPO-1 inhibitor treatment for relapsed/refractory multiple myeloma.
Designed in collaboration with Antengene (AUS) Pty Ltd, Myeloma Australia and healthcare professionals, the program complements the care provided by their hospital-based treating team in achieving optimal patient outcomes.
Activating Patients with Uncontrolled Asthma
Wednesday, November 8, 2023
Atlantis Health presented a poster at the 2023 New Zealand Branch Meeting of the Thoracic Society of Australia and New Zealand and the Australian and New Zealand Society of Respiratory Science.
The poster describes the targeted approach and positive results of a patient activation program developed in partnership with Asthma NZ and DrInfo that identified and mobilized patients with uncontrolled asthma to see their GP.
Impact of a Patient Support Program on Patient Beliefs About Neovascular Age-Related Macular Degeneration and Persistence to Anti-Vascular Endothelial Growth Factor Therapy
Friday, March 5, 2021
This published study compares treatment persistence between patients prescribed intravitreal aflibercept (IVT-AFL) for neovascular age-related macular degeneration (nAMD) in Australia who enrolled on the patient support program (PSP) designed and delivered by Atlantis Health with persistence in a 10% sample of patients from the Australian Pharmaceutical Benefits Scheme (PBS) dataset. Patients in the PSP showed 88% persistence after two years on treatment as compared to 64% persistence after two years in the PBS sample. PSP patients also showed improved beliefs about nAMD disease and its treatment over the course of the program.
Designing a Personalized Digital Patient Support Program for Patients Treated With Growth Hormone: Key Design Considerations
Thursday, August 20, 2020
Recombinant human growth hormone treatment can optimize growth potential; however, optimal outcomes are not always achieved for several reasons, including poor adherence. This paper describes how the steps of the behavior change wheel were applied to the development of a personalized patient support program designed to maximize the chances of treatment success for people with growth hormone deficiency.
CareKnowDo: A pilot Randomized Controlled Trial of multichannel support for people with Chronic Kidney Disease
Tuesday, September 10, 2019
Chronic Kidney Disease (CKD) is a common, progressive condition. Lifestyle changes and antihypertensive medication can delay progression to Stage 5 (end stage) when transplant or ongoing renal replacement therapy is needed, and is fatal if untreated. However, adherence to these recommendations is often low.
Atlantis Health, in collaboration with the UK’s National Health Service (NHS), developed CareKnowDo, an online support tool that provides educational guidance for people with CKD as well as an integrated view of their pre-existing Electronic Health Record, Renal Patient View (PV). The study poster was presented at the 2019 European Health Psychology Society conference in Dubrovik, Croatia.
“It’s like having a friend in your pocket”: Refining CBT-informed Digital Support for People with Autoimmune Conditions
Wednesday, April 10, 2019
Mood disorders are common among patients with autoimmune conditions such as Rheumatoid Arthritis and Crohn’s Disease, and is associated with poor medication adherence and limitations to physical, social, and role functioning.
Atlantis Health presented a poster at the 2019 CBC Conference in London demonstrating that using electronic delivery of CBT (eCBT) for sub-clinical low mood may be an effective way to promote adaptive coping for physical and emotional aspects of autoimmune disease management.
Supporting Patients Treated with Growth Hormone to Reach Their Growth Potential: Personalized Behavior Change Programs
Thursday, November 29, 2018
Recombinant human growth hormone (r-hGH) treatment can optimize growth potential; however, optimum outcomes are not always achieved owing to several reasons, including poor adherence.
Atlantis Health co-authored a poster that was presented at the 2018 European Society for Paediatric Endocrinology conference, identifying key psychosocial factors and interventions to address these barriers through personalized behavioral patient-support programs.
What Drives Severe Hemophilia Patients’ Decision to Change Treatment?
Friday, September 7, 2018
Hemophilia patients face many challenges when considering the best treatment for them. Atlantis Health presented a poster at the 2018 European Health Psychology Society conference some new insights into hemophilia patient beliefs about treatment, and the influence these have on treatment decision making.